Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use

Journal of Infection in Developing Countries

Volumn 9, Issue 3, 2015, Pages 309-312

  Ulu Kilic, Aysegul ^a   Alp, Emine ^a   Altun, Dilek ^a   Cevahir, Fatma ^a   Kalın, Gamze ^a   Demiraslan, Hayati ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Infection; Pseudomonas aeruginosa; Tigecycline

Indexed keywords

TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; ANALOGS AND DERIVATIVES; ANIMAL; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCHOOL CHILD; PSEUDOMONAS INFECTIONS; RISK ASSESSMENT; TERTIARY CARE CENTER; TURKEY; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INFANT; MALE; MIDDLE AGED; MINOCYCLINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TERTIARY CARE CENTERS; TURKEY; YOUNG ADULT;

EID: 84924856426     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.4700     Document Type: Article

References (13)

1. Martin-Gandul C, Garcia-Cabrera E, Castillo-Ojeda E, Jimenez-Mejias ME (2012) More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. J Antimicrob Chemother 67: 1048-1049.
2. Vardakas KZ, Rafailidis PI, Falagas ME (2012) Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 54: 1672-1674.
3. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16: 128-140.
4. Gransden WR, Leibovici L, Eykyn SJ, Pitlik SD, Samra Z, Konisberger H, Drucker M, Phillips I (1995) Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. Clin Microbiol Infect 1: 119-123.
5. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50: 43-48.
6. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 38: 670-677.
7. Miliani K, L'Heriteau F, Lacave L, Carbonne A, Astagneau P (2011) Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. J Hosp Infect 77: 343-347.
8. Cohen MJ, Block CS, Moses AE, Nir-Paz R (2014) Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. Clin Microbiol Infect 20: O188-196.
9. Garcia-Cabrera E, Jimenez-Mejias ME, Gil Navarro MV, Gomez-Gomez MJ, Ortiz-Leyba C, Cordero E, Pachon J (2010) Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 29: 867-871.
10. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E (2005) A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intraabdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 5: 88.
11. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G (2005) Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9: 251-261.
12. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66: 1963-1971.
13. Dixit D, Madduri RP, Sharma R (2014) The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12: 397-400.